Next Article in Journal
Bioaccessibility, Intestinal Permeability and Plasma Stability of Isorhamnetin Glycosides from Opuntia ficus-indica (L.)
Next Article in Special Issue
Antioxidant Artemisia princeps Extract Enhances the Expression of Filaggrin and Loricrin via the AHR/OVOL1 Pathway
Previous Article in Journal
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia
Previous Article in Special Issue
Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(8), 1814;

The Herbal Bitter Drug Gentiana lutea Modulates Lipid Synthesis in Human Keratinocytes In Vitro and In Vivo

Department of Dermatology, Medical Center, Faculty of Medicine, University of Freiburg, 79085 Breisgau, Germany
Flavex Naturextrakte GmbH, 66780 Rehlingen, Germany
BSI-Beauty Science Intelligence GmbH, 30855 Langenhagen, Germany
Author to whom correspondence should be addressed.
Received: 28 June 2017 / Revised: 26 July 2017 / Accepted: 15 August 2017 / Published: 22 August 2017
(This article belongs to the Special Issue Inflammatory Skin Conditions 2017)
Full-Text   |   PDF [2809 KB, uploaded 22 August 2017]   |  


Gentiana lutea is a herbal bitter drug that is used to enhance gastrointestinal motility and secretion. Recently we have shown that amarogentin, a characteristic bitter compound of Gentiana lutea extract (GE), binds to the bitter taste receptors TAS2R1 and TAS2R38 in human keratinocytes, and stimulates the synthesis of epidermal barrier proteins. Here, we wondered if GE also modulates lipid synthesis in human keratinocytes. To address this issue, human primary keratinocytes were incubated for 6 days with GE. Nile Red labeling revealed that GE significantly increased lipid synthesis in keratinocytes. Similarly, gas chromatography with flame ionization detector indicated that GE increases the amount of triglycerides in keratinocytes. GE induced the expression of epidermal ceramide synthase 3, but not sphingomyelinase. Lipid synthesis, as well as ceramide synthase 3 expression, could be specifically blocked by inhibitors of the p38 MAPK and PPARγ signaling pathway. To assess if GE also modulates lipid synthesis in vivo, we performed a proof of concept half side comparison on the volar forearms of 33 volunteers. In comparison to placebo, GE significantly increased the lipid content of the treated skin areas, as measured with a sebumeter. Thus, GE enhances lipid synthesis in human keratinocytes that is essential for building an intact epidermal barrier. Therefore, GE might be used to improve skin disorders with an impaired epidermal barrier, e.g., very dry skin and atopic eczema. View Full-Text
Keywords: keratinocytes; Gentiana lutea; lipid synthesis; p38 MAPK; PPARγ; ceramide synthase 3 keratinocytes; Gentiana lutea; lipid synthesis; p38 MAPK; PPARγ; ceramide synthase 3

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Wölfle, U.; Haarhaus, B.; Seiwerth, J.; Cawelius, A.; Schwabe, K.; Quirin, K.-W.; Schempp, C.M. The Herbal Bitter Drug Gentiana lutea Modulates Lipid Synthesis in Human Keratinocytes In Vitro and In Vivo. Int. J. Mol. Sci. 2017, 18, 1814.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top